Loading company
Just reported
From Intellia Therapeutics's results release of November 5, 2026; its quarterly report has since been filed.
Actual
$7.2M
-48% y/y
-6.5% q/q
Guided
—
No guide given
Actual
-$0.91
Guided
—
No guide given
Actual
-$122.3M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Intellia Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$47.5BA+
EXELExelixis, Inc.$17BA+
JAZZJazz Pharmaceuticals plc$15.4BA
HALOHalozyme Therapeutics, Inc.$11.5BA+
TECHBIO-Techne Corp$11.4BA+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now ABuilt from Intellia Therapeutics, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
Grade D-
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 32 quarters of Intellia Therapeutics, Inc.’s grade history. The other 30 go back to February 2019.
